FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896441111> ?p ?o ?g. }

• W2896441111 endingPage "495" @default.
• W2896441111 startingPage "486" @default.
• W2896441111 abstract "No AccessJournal of UrologyAdult Urology1 Mar 2019Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen Sam Li-Sheng Chen, Jean Ching-Yuan Fann, Csilla Sipeky, Teng-Kai Yang, Sherry Yueh-Hsia Chiu, Amy Ming-Fang Yen, Virpi Laitinen, Teuvo L. J. Tammela, Ulf-Håkan Stenman, Anssi Auvinen, Johanna Schleutker, and Hsiu-Hsi Chen Sam Li-Sheng ChenSam Li-Sheng Chen School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei More articles by this author , Jean Ching-Yuan FannJean Ching-Yuan Fann Department of Health Industry Management, School of Healthcare Management, Kainan University, Tao-Yuan, Taiwan More articles by this author , Csilla SipekyCsilla Sipeky Department of Medical Biochemistry and Genetics, Institute of Biomedicine, University of Turku, Turku More articles by this author , Teng-Kai YangTeng-Kai Yang Department of Urology, National Taiwan University Hospital, Taipei Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei More articles by this author , Sherry Yueh-Hsia ChiuSherry Yueh-Hsia Chiu Department and Graduate Institute of Health Care Management, College of Management, Chang Gung University, Tao-Yuan, Taiwan More articles by this author , Amy Ming-Fang YenAmy Ming-Fang Yen School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei More articles by this author , Virpi LaitinenVirpi Laitinen Institute of Biomedical Technology/BioMediTech, University of Tampere, Tampere More articles by this author , Teuvo L. J. TammelaTeuvo L. J. Tammela Faculty of Medicine and Biosciences, University of Tampere, Tampere Department of Urology, Tampere University Hospital, Tampere More articles by this author , Ulf-Håkan StenmanUlf-Håkan Stenman Department of Clinical Chemistry, Helsinki University Central Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland More articles by this author , Anssi AuvinenAnssi Auvinen Section of Health Sciences, Faculty of Social Sciences, University of Tampere, Tampere More articles by this author , Johanna SchleutkerJohanna Schleutker Department of Medical Genetics, Turku University Hospital, Turku More articles by this author , and Hsiu-Hsi ChenHsiu-Hsi Chen *Correspondence and requests for reprints: Division of Biostatistics, Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Room 533, 5F, No. 17 Suchow Rd., Taipei100, Taiwan (telephone: +886-2-33228033; FAX: +886-2-23587707; e-mail: E-mail Address: [email protected]). Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.10.015AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Combined information on single nucleotide polymorphisms and prostate specific antigen offers opportunities to improve the performance of screening by risk stratification. We aimed to predict the risk of prostate cancer based on prostate specific antigen together with single nucleotide polymorphism information. Materials and Methods: We performed a prospective study of 20,575 men with prostate specific antigen testing and 4,967 with a polygenic risk score for prostate cancer based on 66 single nucleotide polymorphisms from the Finnish population based screening trial of prostate cancer and 5,269 samples of 7 single nucleotide polymorphisms from the Finnish prostate cancer DNA study. A Bayesian predictive model was built to estimate the risk of prostate cancer by sequentially combining genetic information with prostate specific antigen compared with prostate specific antigen alone in study subjects limited to those with prostate specific antigen 4 ng/ml or above. Results: The posterior odds of prostate cancer based on 7 single nucleotide polymorphisms together with the prostate specific antigen level ranged from 3.7 at 4 ng/ml, 14.2 at 6 and 40.7 at 8 to 98.2 at 10 ng/ml. The ROC AUC was elevated to 88.8% (95% CI 88.6–89.1) for prostate specific antigen combined with the risk score based on 7 single nucleotide polymorphisms compared with 70.1% (95% CI 69.6–70.7) for prostate specific antigen alone. It was further escalated to 96.7% (95% CI 96.5–96.9) when all prostate cancer susceptibility polygenes were combined. Conclusions: Expedient use of multiple genetic variants together with information on prostate specific antigen levels better predicts the risk of prostate cancer than prostate specific antigen alone and allows for higher prostate specific antigen cutoffs. Combined information also provides a basis for risk stratification which can be used to optimize the performance of prostate cancer screening. Reference 1. : A common variant associated with prostate cancer in European and African populations. Nat Genet 2006; 38: 652. Google Scholar 2. : Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007; 39: 638. Google Scholar 3. : Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39: 645. Google Scholar 4. : Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007; 39: 631. Google Scholar 5. : Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39: 977. Google Scholar 6. : Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358: 910. Google Scholar 7. : Multigene panels in prostate cancer risk assessment: a systematic review. Genet Med 2016; 18: 535. Google Scholar 8. : Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981. Google Scholar 9. : Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310. Google Scholar 10. : Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst 2013; 105: 719. Google Scholar 11. : The Finnish trial of prostate cancer screening: where are we now?BJU Int 2003; 92: 22. Google Scholar 12. : A stochastic model for survival of early prostate cancer with adjustments for leadtime, length bias, and over-detection. Biom J 2012; 54: 20. Google Scholar 13. : Multiple loci identified in a genomewide association study of prostate cancer. Nat Genet 2008; 40: 310. Google Scholar 14. : Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012; 12; 366: 141. Google Scholar 15. : HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2013; 22: 452. Google Scholar 16. : Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. Br J Cancer 2015; 113: 1086. Google Scholar 17. : Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet 2018; 50: 928. Google Scholar 18. : Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease. Clin Chim Acta 2010; 411: 1232. Google Scholar 19. : Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. Ann Oncol 2015; 26: 756. Google Scholar 20. : Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 2000; 163: 1144. Link, Google Scholar 21. : Significance of prostate-specific antigen-alpha(1)-antichymotrypsin complex for diagnosis and staging of prostate cancer. Jpn J Clin Oncol 2001; 31: 506. Google Scholar 22. : Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003; 349: 335. Google Scholar 23. : Predictive properties of serum-prostate-specific antigen testing in a community-based setting. Arch Intern Med 1996; 156: 2462. Google Scholar 24. : Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996; 335: 304. Google Scholar 25. : Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: results from the prostate cancer prevention trial. Prostate 2016; 76: 1120. Google Scholar The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number. Supported by the Ministry of Science and Technology (grant number MOST 107-3017-F-002-003) and the “Innovation and Policy Center for Population Health and Sustainable Environment (Population Health Research Center, PHRC), College of Public Health, National Taiwan University” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (NTU-107L9003). No direct or indirect commercial, personal, academic, political, religious or ethical incentive is associated with publishing this article. © 2019 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 201Issue 3March 2019Page: 486-495Supplementary Materials Advertisement Copyright & Permissions© 2019 by American Urological Association Education and Research, Inc.Keywordsprostatic neoplasmsmass screeningpolymorphismsingle nucleotideprostate-specific antigenriskMetricsAuthor Information Sam Li-Sheng Chen School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei More articles by this author Jean Ching-Yuan Fann Department of Health Industry Management, School of Healthcare Management, Kainan University, Tao-Yuan, Taiwan More articles by this author Csilla Sipeky Department of Medical Biochemistry and Genetics, Institute of Biomedicine, University of Turku, Turku More articles by this author Teng-Kai Yang Department of Urology, National Taiwan University Hospital, Taipei Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei More articles by this author Sherry Yueh-Hsia Chiu Department and Graduate Institute of Health Care Management, College of Management, Chang Gung University, Tao-Yuan, Taiwan More articles by this author Amy Ming-Fang Yen School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei More articles by this author Virpi Laitinen Institute of Biomedical Technology/BioMediTech, University of Tampere, Tampere More articles by this author Teuvo L. J. Tammela Faculty of Medicine and Biosciences, University of Tampere, Tampere Department of Urology, Tampere University Hospital, Tampere More articles by this author Ulf-Håkan Stenman Department of Clinical Chemistry, Helsinki University Central Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland More articles by this author Anssi Auvinen Section of Health Sciences, Faculty of Social Sciences, University of Tampere, Tampere More articles by this author Johanna Schleutker Department of Medical Genetics, Turku University Hospital, Turku More articles by this author Hsiu-Hsi Chen Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei *Correspondence and requests for reprints: Division of Biostatistics, Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Room 533, 5F, No. 17 Suchow Rd., Taipei100, Taiwan (telephone: +886-2-33228033; FAX: +886-2-23587707; e-mail: E-mail Address: [email protected]). More articles by this author Expand All The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number. Supported by the Ministry of Science and Technology (grant number MOST 107-3017-F-002-003) and the “Innovation and Policy Center for Population Health and Sustainable Environment (Population Health Research Center, PHRC), College of Public Health, National Taiwan University” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (NTU-107L9003). No direct or indirect commercial, personal, academic, political, religious or ethical incentive is associated with publishing this article. Advertisement PDF downloadLoading ..." @default.
• W2896441111 created "2018-10-26" @default.
• W2896441111 creator A5007111631 @default.
• W2896441111 creator A5009503576 @default.
• W2896441111 creator A5013553631 @default.
• W2896441111 creator A5027297522 @default.
• W2896441111 creator A5029422912 @default.
• W2896441111 creator A5030754741 @default.
• W2896441111 creator A5035627161 @default.
• W2896441111 creator A5041331122 @default.
• W2896441111 creator A5049507000 @default.
• W2896441111 creator A5069216404 @default.
• W2896441111 creator A5073976193 @default.
• W2896441111 creator A5082556049 @default.
• W2896441111 date "2019-03-01" @default.
• W2896441111 modified "2023-09-26" @default.
• W2896441111 title "Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen" @default.
• W2896441111 doi "https://doi.org/10.1016/j.juro.2018.10.015" @default.
• W2896441111 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30366021" @default.
• W2896441111 hasPublicationYear "2019" @default.
• W2896441111 type Work @default.
• W2896441111 sameAs 2896441111 @default.
• W2896441111 citedByCount "21" @default.
• W2896441111 countsByYear W28964411112019 @default.
• W2896441111 countsByYear W28964411112020 @default.
• W2896441111 countsByYear W28964411112021 @default.
• W2896441111 countsByYear W28964411112022 @default.
• W2896441111 countsByYear W28964411112023 @default.
• W2896441111 crossrefType "journal-article" @default.
• W2896441111 hasAuthorship W2896441111A5007111631 @default.
• W2896441111 hasAuthorship W2896441111A5009503576 @default.
• W2896441111 hasAuthorship W2896441111A5013553631 @default.
• W2896441111 hasAuthorship W2896441111A5027297522 @default.
• W2896441111 hasAuthorship W2896441111A5029422912 @default.
• W2896441111 hasAuthorship W2896441111A5030754741 @default.
• W2896441111 hasAuthorship W2896441111A5035627161 @default.
• W2896441111 hasAuthorship W2896441111A5041331122 @default.
• W2896441111 hasAuthorship W2896441111A5049507000 @default.
• W2896441111 hasAuthorship W2896441111A5069216404 @default.
• W2896441111 hasAuthorship W2896441111A5073976193 @default.
• W2896441111 hasAuthorship W2896441111A5082556049 @default.
• W2896441111 hasBestOaLocation W28964411112 @default.
• W2896441111 hasConcept C104317684 @default.
• W2896441111 hasConcept C121608353 @default.
• W2896441111 hasConcept C126322002 @default.
• W2896441111 hasConcept C135763542 @default.
• W2896441111 hasConcept C143998085 @default.
• W2896441111 hasConcept C147483822 @default.
• W2896441111 hasConcept C153209595 @default.
• W2896441111 hasConcept C203014093 @default.
• W2896441111 hasConcept C2776235491 @default.
• W2896441111 hasConcept C2780192828 @default.
• W2896441111 hasConcept C2781406297 @default.
• W2896441111 hasConcept C54355233 @default.
• W2896441111 hasConcept C71924100 @default.
• W2896441111 hasConcept C86803240 @default.
• W2896441111 hasConcept C87874733 @default.
• W2896441111 hasConceptScore W2896441111C104317684 @default.
• W2896441111 hasConceptScore W2896441111C121608353 @default.
• W2896441111 hasConceptScore W2896441111C126322002 @default.
• W2896441111 hasConceptScore W2896441111C135763542 @default.
• W2896441111 hasConceptScore W2896441111C143998085 @default.
• W2896441111 hasConceptScore W2896441111C147483822 @default.
• W2896441111 hasConceptScore W2896441111C153209595 @default.
• W2896441111 hasConceptScore W2896441111C203014093 @default.
• W2896441111 hasConceptScore W2896441111C2776235491 @default.
• W2896441111 hasConceptScore W2896441111C2780192828 @default.
• W2896441111 hasConceptScore W2896441111C2781406297 @default.
• W2896441111 hasConceptScore W2896441111C54355233 @default.
• W2896441111 hasConceptScore W2896441111C71924100 @default.
• W2896441111 hasConceptScore W2896441111C86803240 @default.
• W2896441111 hasConceptScore W2896441111C87874733 @default.
• W2896441111 hasIssue "3" @default.
• W2896441111 hasLocation W28964411111 @default.
• W2896441111 hasLocation W28964411112 @default.
• W2896441111 hasLocation W28964411113 @default.
• W2896441111 hasOpenAccess W2896441111 @default.
• W2896441111 hasPrimaryLocation W28964411111 @default.
• W2896441111 hasRelatedWork W1497253641 @default.
• W2896441111 hasRelatedWork W2017040238 @default.
• W2896441111 hasRelatedWork W2021846196 @default.
• W2896441111 hasRelatedWork W2082569851 @default.
• W2896441111 hasRelatedWork W2131098924 @default.
• W2896441111 hasRelatedWork W2170823000 @default.
• W2896441111 hasRelatedWork W2354678759 @default.
• W2896441111 hasRelatedWork W2475064925 @default.
• W2896441111 hasRelatedWork W4282843086 @default.
• W2896441111 hasRelatedWork W4383737431 @default.
• W2896441111 hasVolume "201" @default.
• W2896441111 isParatext "false" @default.
• W2896441111 isRetracted "false" @default.
• W2896441111 magId "2896441111" @default.
• W2896441111 workType "article" @default.